Immune checkpoint proteins (ICPs) serve as critical regulators of the immune system,
ensuring protection against damage due to overly activated immune responses. However …

During tumorigenesis and progression, the immune checkpoint programmed death-1 (PD-1)
and its ligand programmed death ligand-1 (PD-L1) play critical roles in suppressing T cell …

Over the last 13 years, the use of immune checkpoint inhibitor (ICI) therapy has grown
remarkably, owing to their unprecedented anti-tumor efficacy in certain tumor groups. With …

Background Co-inhibition of immune checkpoints lymphocyte-activation gene 3 (LAG-3) and
PD-1 is believed to enhance cancer immunotherapy through synergistic effects. Herein, we …

Background Increased understanding of how the immune system regulates tumor growth
has innovated the use of immunotherapeutics to treat various cancers. The impact of such …

In recent years, ICIs have transformed cancer treatment by harnessing the body's immune
system to target and destroy cancer cells (1–3). ICIs work by blocking inhibitory signals that …

Background Magnesium deficiency influences the activation and cytotoxicity of immune
cells. Nevertheless, whether serum magnesium levels influence the clinical outcomes of …

Objectives Killer cell lectin like receptor G1 (KLRG1) is identified as a co-inhibitory receptor
for NK cells and antigen-experienced T cells. The role of KLRG1 in immune regulation in …

Simple Summary Cancer treatment with immune checkpoint inhibitors (ICIs) has significantly
impacted patients' management and outcomes. To better assess the benefit of ICIs and …

The immunosuppressive characteristics and acquired immune resistance can restrain the
therapy‐initiated anti‐tumor immunity. In this work, an antibody free programmed death …